US89422G1076 - Common Stock
TRAVERE THERAPEUTICS INC
NASDAQ:TVTX (4/25/2024, 4:32:00 PM)
After market: 5.45 +0.06 (+1.11%)5.39
-0.06 (-1.1%)
Travere Therapeutics, Inc. is a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 462 full-time employees. The company went IPO on 2003-07-23. The firm is focused on identifying, developing and delivering therapies to people living with rare kidney, liver, and metabolic diseases. The Company’s products are Thiola and Thiola EC (tiopronin tablets) used for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The firm has received approval of FILSPARI (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin 1 and angiotensin-II) and is a non-immunosuppressive therapy approved for the treatment of this condition. FILSPARI (sparsentan) is a dual endothelin angiotensin receptor antagonist (DEARA). Sparsentan has been granted Orphan Drug Designation for the treatment of IgAN in the United States and Europe.
TRAVERE THERAPEUTICS INC
3611 Valley Centre Dr, Suite 300
San Diego CALIFORNIA 92130
P: 18889697879
CEO: Eric M. Dube
Employees: 462
Website: https://travere.com/
Travere and CSL Vifor announce EC approval of FILSPARI (sparsentan) for treatment of IgAN, 1st non-immunosuppressive treatment for IgAN approved in...
/CNW/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing authorization...
/PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional marketing...
Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria
Travere to present abstracts at SIMD and GMDI highlighting research investigating pegtibatinase as the first potential disease-modifying therapy for HCU...
Here you can normally see the latest stock twits on TVTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: